Open AccessInosine Monophosphate Dehydrogenase Polymorphisms and Renal Allograft Outcome
Author(s) -
Sapna Shah,
Steven Harwood,
Bernd Döhler,
Gerhard Opelz,
Muhammad Yaqoob
Publication year - 2012
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/tp.0b013e31825b7654
Subject(s) - imp dehydrogenase , mycophenolic acid , cohort , transplantation , mycophenolate , single nucleotide polymorphism , medicine , inosine , allele , pharmacology , pharmacogenetics , genotype , biology , genetics , gene , adenosine
Interindividual variation in inosine monophosphate dehydrogenase (IMPDH) enzyme activity and adverse effects caused by mycophenolate mofetil (MMF) inhibition may be genetically determined, and if so, transplant recipients should receive personalized dosing regimens of MMF, which would maximize efficacy and minimize toxicity. Some studies have demonstrated a relationship between the single nucleotide polymorphism and the risk of acute rejection with IMPDH I variants rs2278293 and rs2278294 and IMPDH II variant rs11706052, whereas others have failed to exhibit an effect. The aim of this work was to investigate the influence of these polymorphisms on acute rejection rates, graft survival and function, and MMF doses in a large cohort of patients.